Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event ...

FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial. Later this ...

The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...

In this target trial emulation study, denosumab was associated with an increased risk of major adverse cardiovascular events ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will ...